Pipes, pumps and
values are only part of the drinking water story we began telling last week on
March 22nd in the post “Water Works.” The Ecological
Society of America estimates that the U.S. spends more
than $2 billion annually on clean water projects in an attempt to prevent
pollution and clean contaminated water.
Water quality is a diverse market, beginning with projects to promote
natural ecosystems which are the ultimate ‘water filter.’ The market extends to water treatment
facilities, filtration systems and purification technologies among other
solutions to ensure that our drinking water is safe.
The market for
water quality solutions is highly fragmented with numerous small operators,
often with some engineering or technological expertise, addressing the peculiar
water issues in their immediate locale.
Few companies have gains national or international scale, save for those
large engineering firms that have broad interests in a variety of civil
engineering projects. Most of the
players are private, leaving few options for investors to take a ‘pure play’
position in water quality. Nonetheless,
we found one private player that offers some interesting water quality
solutions. Two more public companies
provide good plays on water.
Headquartered in
Pennsylvania, Evoqua Water
Technologies has built a network of 170 sales offices and
production facilities in eight countries. Evoqua sells a mix of water and waste
water treatment products such as activated carbon and sludge thickener or
disintegration products. The company
also sells a broad selection of systems for biological treatment of water,
waste water handling, aeration and anaerobic digestion, among other equipment
and components. Engineering and project
integration services to commission, maintain and optimize water and waste water
facilities. Besides catering to the
municipal drinking water and waste water market, the company also serves
various industry verticals such as aquatics, food and beverage, pharmaceuticals
and chemicals processing, among others.
Recently, Evoqua
won contracts to build four wastewater treatment plants that will expand the capacity
of three different communities and one private agricultural company. The company’s Davco-branded field-erected
treatment solution will be installed in each site for expansion of existing
facilities.
Unfortunately,
there is no public data available on the company’s financial performance or
market share. That said we believe it is
highly likely that the company is profitable and has been successful enough to
generate strong cash flows that have funded the company’s expansion beyond its home
market in the U.S. With its brand presence
on several continents, we expect Evoqua to eventually end up on someone’s radar,
either for a move to the public capital market or as an acquisition target.
Xylem, Inc. (XYL:
NYSE) does provide a publicly traded
stock for investors interested in the water market. In the most recently reported twelve months
ending December 2015, Xylem reported $3.65 billion in revenue from the sales of
water infrastructure and equipment, providing $340 million in net income. That represents a net profit margin of
9.3%. The conversion of 12.7% of sales
to operating cash flow is even more impressive.
The company got
its start with an innovative submersible wastewater pump, parlaying that
leading edge technology into a broad range of water and waste water systems and
components. Among the menu of products
Xylem sells, is a selection of treatment systems and analytical instruments
that address water contamination issues.
Xylem provides filtration, biological treatment and desalination
solutions. The company has systems or
products in use in over 150 different countries.
Xylem is no
small-cap. It has earned a market
capitalization of $7.4 billion or 2.0 times sales. That may seem pricey, but we note that the
stock is trading at 18.8 times projected earnings of $2.00 in earnings per
share in 2016. A forward dividend yield
of 1.7% helps sweeten the pot. Forward
price multiples in the water and waste water industry also suggest Xylem is
priced a bit dear. The sector is
commanding valuations only 11.8 times 2016 earnings estimates.
A significant competitor
for Xylem is Danaher
Corporaton (DHR: NYSE),
which is an even bigger company with products and services well beyond the
water market. Danaher describes its
business as a science and technology operation.
In a few words its product line falls under test instruments,
environmental products and services and life sciences products. Danaher can measure the quality of the water
at your tap so you can brush your teeth with confidence. They can also provide products to fix your
teeth. That wide array of products earned
Danaher $20.6 billion in revenue in the year 2015.
Danaher is on
the calendar to report financial results for the March 2016 quarter on April 21st. Analysts are expecting Danaher to report a
buck in net earnings per share. Given
that the company has met or exceeded the consensus estimate in each of the last
four quarters, that $1.00 EPS figure seems like a safe bet.
Likewise Danaher
is trading at a healthy 17.9 times the full year 2016 EPS estimate of $4.88 per
share. A forward dividend yield of 0.7%
helps make the case for DHR.
Neither the author of the Small Cap Strategist web
log, Crystal Equity Research nor its affiliates have a beneficial interest in
the companies mentioned herein.
No comments:
Post a Comment